Imagion Biosystems Ltd has released a press release.
Appendix 4D and Half Year Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Imagion Biosystems receives A$2 million in R&D tax incentive
- FDA Breakthrough Device Designation
- Imagion Biosystems successfully completes toxicology study
- Imagion Biosystems receives R&D Advanced Overseas Finding
- IBX receives order related to cancer treatment
Later from Imagion Biosystems
- Investor Presentation
- Pro-Rata Renounceable Rights Issue - Amended Timetable
- Completion of Renounceable Rights Issue
- Response to ASX price query
- Business Update - Manufacturing commences
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems